Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease

Background Dipeptidyl peptidase-4 (DPP4) inhibitors are frequently prescribed for patients with type 2 diabetes; however, their cost can pose a significant barrier for those with impaired kidney function. This study aimed to estimate the economic benefits of substituting non-renal dose-adjusted (NRD...

Cijeli opis

Bibliografski detalji

Glavni autori:	Hun Jee Choe, Yeh-Hee Ko, Sun Joon Moon, Chang Ho Ahn, Kyoung Hwa Ha, Hyeongsuk Lee, Jae Hyun Bae, Hyung Joon Joo, Hyejin Lee, Jang Wook Son, Dae Jung Kim, Sin Gon Kim, Kwangsoo Kim, Young Min Cho
Format:	Artigo
Jezik:	Inglês
Izdano:	Korean Endocrine Society 2024-08-01
Serija:	Endocrinology and Metabolism
Teme:	cost savings dipeptidyl-peptidase iv inhibitors renal insufficiency, chronic diabetes mellitus, type 2 common data model
Online pristup:	http://www.e-enm.org/upload/pdf/enm-2024-1965.pdf
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!